Kymera Therapeutics, Inc. (NASDAQ:KYMR) Receives Consensus Rating of “Moderate Buy” from Analysts
Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR – Get Free Report) have earned an average rating of “Moderate Buy” from the fifteen research firms that are currently covering the firm, Marketbeat reports. Three research analysts have rated the stock with a hold recommendation, eleven have given a buy recommendation and one has given a strong buy […]
Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR – Get Free Report) have earned an average rating of “Moderate Buy” from the fifteen research firms that are currently covering the firm, Marketbeat reports. Three research analysts have rated the stock with a hold recommendation, eleven have given a buy recommendation and one has given a strong buy […]
